Broadcast

Visitation Alert

Back

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (Pediatric MATCH)

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes

  • Clinical Trial Information

    Trial Contact: Spinelli, Jennifer; Leffin, Melissa; El-Shami, Jessica

  • IRB No: APEC1621H

    Protocol Abbrev: APEC1621H

    Principal Investigator: Amy A Smith, MD

    Phase: Drug: Phase II

    Age Group: Adult;Pediatric

    Secondary Protocol No: APEC1621H

    Treatment: Drug: Olaparib

    Therapies Involved: Chemotherapy

    ClinicalTrials.gov ID: NCT03233204

  • Objective

    To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with olaparib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in the deleterious genetic alterations in the DNA damage repair (DDR) pathway.

  • Key Eligibility

    Ages Eligible for Study: 12 Months to 21 Years (Child, Adult)
    Sexes Eligible for Study: All
    Accepts Healthy Volunteers: No